title: Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure.
abstract: BACKGROUND
  Cystatin C (CysC) is a good prognostic marker in heart failure. However, there is not much information of CysC combined with other biomarkers in acute heart failure (AHF).
  
  
  OBJECTIVE
  To assess prognostic value of CysC and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients hospitalized for AHF with no apparent deterioration of renal function.
  
  
  METHODS
  Prospective, multicenter, observational study.
  
  
  METHODS
  CysC and NTpro-BNP were measured in patients consecutively admitted with a diagnosis of AHF. Patients with, NTpro-BNP concentration above 900 pg/mL and serum creatinine below 1.3mg/dL, were included for statistical analysis. End-point of the study was all-cause mortality during a 12-month follow-up.
  
  
  RESULTS
  526 patients with AHF and NTpro-BNP concentration above 900 pg/mL were included in the study. From this group, 367 patients (69.8%) had serum creatinine below 1.3mg/dL. Receiver operating characteristic (ROC) curves were used to determine the best cut-off value for CysC. Patients with a concentration of CsyC above 1.25mg/dL had a 37.8% mortality rate, vs. 13.6% for those below cut-off (p<0.001). After Cox proportional hazard model, age, CysC, low total cholesterol and HF with preserved ejection fraction remained significantly associated with all-cause mortality during one-year follow-up.
  
  
  CONCLUSIONS
  In AHF and normal or slightly impaired renal function, performance of CysC may be superior to NT-proBNP. Hence, CysC may be the preferred biomarker in the assessment of patients with AHF and slightly impaired renal function.
authors.affiliation: Servicio de Medicina Interna, Hospital Clínico Universitario "Lozano Blesa", Facultad de Medicina, Universidad de Zaragoza, Spain. jiperez@unizar.es
authors.forename: Juan Ignacio
authors.initials: JI
authors.lastname: Pérez-Calvo
authors.forename: Francisco José
authors.initials: FJ
authors.lastname: Ruiz-Ruiz
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Carrasco-Sánchez
authors.forename: José Luis
authors.initials: JL
authors.lastname: Morales-Rull
authors.forename: Sergio
authors.initials: S
authors.lastname: Manzano-Fernández
authors.forename: Luis
authors.initials: L
authors.lastname: Galisteo-Almeda
authors.forename: Domingo
authors.initials: D
authors.lastname: Pascual-Figal
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D003404:Creatinine / Q000097:blood; D055316:Cystatin C / Q000097:blood*; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D006801:Humans; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012372:ROC Curve
chemical_list: D015415:Biomarkers; C525030:CST3 protein, human; D055316:Cystatin C; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D003404:Creatinine